Klin Farmakol Farm. 2020;34(1):19-22 | DOI: 10.36290/far.2020.006

Allogeneic haematopoietic cell transplantation from the perspective of pharmacotherapy

Markéta Marková
Ústav hematologie a krevní transfuze Praha

Allogeneic haematopoietic transplantation is a therapeutic approach being used mostly in the treatment of hematological malignancies. Specific pharmacotherapy is its integral part, including both early peritransplant period and long-term follow-up. In the following text we attempt to summarize its basic principal.

Keywords: allogeneic haematopoietic transplantation, conditioning, graft versus host disease, graft versus leukaemia effect, transplant immunosuppression, supportive care.

Published: April 8, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Marková M. Allogeneic haematopoietic cell transplantation from the perspective of pharmacotherapy. Klin Farmakol Farm. 2020;34(1):19-22. doi: 10.36290/far.2020.006.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rambaldi A, Grassi A, Masciulli A, Boschini C, Micò MC, Busca A, Bruno B, Cavattoni I, Santarone S, Raimondi R, Montanari M, Milone G, Chiusolo P, Pastore D, Guidi S, Patriarca F, Risitano AM, Saporiti G, Pini M, Terruzzi E, Arcese W, Marotta G, Carella AM, Nagler A, Russo D, Corradini P, Alessandrino EP, Torelli GF, Scimè R, Mordini N, Oldani E, Marfisi RM, Bacigalupo A, Bosi A. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem‑cell transplantation in patients with acute myeloid leukaemia: an open‑label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015 Nov; 16(15): 1525-1536. Go to original source...
    2. Martino R, de Wreede L, Fiocco M, van Biezen A, von dem Borne PA, Hamladji RM, Volin L, Bornhäuser M, Robin M, Rocha V, de Witte T, Kröger N, Mohty M; Acute Leukemia Working Party the subcommittee for Myelodysplastic Syndromes of the Chronic Malignancies Working Party of the European group for Blood Marrow Transplantation Group (EBMT). Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA‑identical sibling donors in AML and MDS with
    3. Shimoni A, Nagler A. Optimizing the conditioning regimen for allogeneic stem‑cell transplantation in acute myeloid leukemia; dose intensity is still in need. Best Pract Res Clin Haematol. 2011 Sep; 24(3): 369-379. Go to original source... Go to PubMed...
    4. Slavin S1, Aker M, Shapira MY, Resnick I, Bitan M, Or R. Reduced‑intensity conditioning for the treatment of malignant and life‑threatening non‑malignant disorders. Clin Transpl. 2003: 275-282. Go to PubMed...
    5. Kharfan‑Dabaja M1, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B, Kumar A. Mycophenolate mofetil versus methotrexate for prevention of graft‑versus‑host disease in people receiving allogeneic hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2014 Jul 25; (7). Go to original source... Go to PubMed...
    6. Theurich S1, Fischmann H, Shimabukuro‑Vornhagen A, Chemnitz JM, Holtick U, Scheid C, Skoetz N, von Bergwelt‑Baildon M. Polyclonal anti‑thymocyte globulins for the prophylaxis of graft‑versus‑host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database Syst Rev. 2012 Sep 12; (9). Go to original source... Go to PubMed...
    7. Mielcarek M, Furlong T, O'Donnell PV, Storer BE, McCune JS, Storb R, Carpenter PA, Flowers ME, Appelbaum FR, Martin PJ. Posttransplantation cyclophosphamide for prevention of graft‑versus‑host disease after HLA‑matched mobilized blood cell transplantation. Blood. 2016 Mar 17; 127(11): 1502-1508. doi: 10.1182/blood-2015-10-672071. Go to original source...
    8. Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Pérez de Oteiza J, Duarte R, Carella AM, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Bonifazi F. Antilymphocyte Globulin for Prevention of Chronic Graft‑versus‑Host Disease. N Engl J Med. 2016 Jan 7; 374(1): 43-53. Go to original source...
    9. Baumgartner A, Bargetzi A, Zueger N, Bargetzi M, Medinger M, Bounoure L, Gomes F, Stanga Z, Mueller B, Schuetz P. Revisiting nutritional support for allogeneic hematologic stem cell transplantation‑a systematic review. Bone Marrow Transplant. 2017 Apr; 52(4). Go to original source... Go to PubMed...
    10. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect, DiS. 2011 Feb 15; 52(4): e56-93. o Go to original source... Go to PubMed...
    11. Rudoni J, Jan A, Hosing C, Aung F, Yeh J. Eculizumab for transplant‑associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients. Eur J Haematol. 2018 Sep; 101(3): 389-398. Go to original source... Go to PubMed...
    12. Jodele S, Laskin BL, Dandoy CE, Myers KC, El‑Bietar J, Davies SM, Goebel J, Dixon BP. A new paradigm: Diagnosis and management of HSCT‑associated thrombotic microangiopathy as multi‑system endothelial injury. Blood Rev. 2015 May; 29(3): 191-204. Go to original source... Go to PubMed...
    13. Richardson P, Aggarwal S, Topaloglu O, Villa KF, Corbacioglu S. Systematic review of defibrotide studies in the treatment of veno‑occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). Bone Marrow Transplant. 2019 Feb 25. doi: 10.1038/s41409-019-0474-8. [Epub ahead of print] Erratum in: Bone Marrow Transplant. 2019 Apr 1. Go to original source...
    14. Nassereddine S, Rafei H, Elbahesh E, Tabbara I. Acute Graft Versus Host Disease: A Comprehensive Review. Anticancer Res. 2017 Apr; 37(4): 1547-1555. Go to original source...
    15. Sarantopoulos S, Cardones AR, Sullivan KM. How I treat refractory chronic graft‑versus‑host disease. Blood. 2019 Mar 14; 133(11): 1191-1200. doi: 10.1182/blood-2018-04-785899. Go to original source...
    16. Glotzbecker B, Duncan C, Alyea E 3rd, Campbell B, Soiffer R. Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. Biol Blood Marrow Transplant. 2012 Jul; 18(7): 989-1006. Go to original source...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.